financial
results
corporate
business
update
paris
stock
exchange
iva
cash
cash
equivalents
june
successful
initial
public
offering
nasdaq
global
market
extending
company
cash
runway
initial
public
offering
nasdaq
global
market
extending
company
cash
runway
publication
positive
topline
results
phase
iib
native
clinical
trial
evaluating
lanifibranor
nash
decision
move
pivotal
phase
iii
development
new
data
phase
iib
native
clinical
trial
nash
showing
significant
decrease
fibrosis
apoptosis
inflammation
biomarkers
weeks
treatment
lanifibranor
appointment
dr
arun
sanyal
inventiva
scientific
advisory
board
sab
strengthening
board
expertise
field
nash
acceptance
investigational
new
drug
ind
application
odiparcil
mps
vi
food
drug
administration
fda
enabling
clinical
trials
daix
france
september
inventiva
euronext
paris
nasdaq
iva
biopharmaceutical
company
focused
development
oral
small
molecule
therapies
treatment
steatohepatitis
nash
mucopolysaccharidoses
mps
diseases
significant
unmet
medical
need
today
reported
interim
financial
results
six
months
ended
june
provided
update
business
activities
frédéric
cren
chairman
chief
executive
officer
cofounder
inventiva
stated
first
half
one
decisive
periods
since
founding
inventiva
looking
development
r
portfolio
lead
drug
candidate
lanifibranor
shown
promising
results
phase
iib
clinical
trial
nash
statistically
significant
results
fda
european
medical
agency
ema
primary
endpoints
relevant
seeking
accelerated
approval
phase
iii
clinical
development
trial
paved
way
lanifibranor
enter
pivotal
phase
iii
parallel
progressed
development
odiparcil
treatment
mps
vi
recent
acceptance
ind
application
fda
allow
us
launch
first
clinical
trial
odiparcil
usa
lay
groundwork
future
development
important
market
would
also
like
thank
whole
inventiva
team
worked
tirelessly
last
months
difficult
context
proud
work
commitment
contributed
achievements
looking
ahead
fully
focused
moving
forward
clinical
development
lanifibranor
nash
anticipated
pivotal
phase
iii
trial
continuing
advance
different
programs
across
mps
psoriasis
oncology
line
jean
volatier
chief
financial
officer
inventiva
added
addition
significant
progress
r
portfolio
especially
nash
also
able
considerably
strengthen
financial
position
despite
challenging
environment
linked
pandemic
particular
note
successful
initial
public
offering
nasdaq
global
market
increases
visibility
key
market
enabled
us
extend
cash
runway
fourth
quarter
backed
solid
financial
position
important
advances
across
r
portfolio
ideal
position
pursue
development
different
drug
key
financial
results
first
half
thousands
euros
except
share
per
share
amounts
june
june
revenue
income
research
development
expenses
marketing
business
development
expenses
general
administrative
expenses
operating
income
expenses
operating
profit
loss
financial
income
loss
income
tax
net
loss
period
basic
diluted
loss
per
share
euros
share
weighted
average
number
outstanding
shares
used
computing
basic
diluted
loss
per
share
revenues
first
half
reached
million
compared
million
first
half
related
primarily
research
services
connection
inventiva
collaboration
boehringer
ingelheim
since
terminated
r
expenses
amounted
million
first
half
compared
first
half
expenses
mainly
dedicated
development
lanifibranor
nash
odiparcil
mps
vi
decrease
compared
previous
year
mainly
due
halt
clinical
development
lanifibranor
treatment
systemic
sclerosis
february
savings
generated
employment
safeguard
plan
subsequently
introduced
first
half
recording
full
effect
savings
generated
general
administrative
expenses
amounted
million
compared
million
first
half
mainly
due
increased
labor
costs
operating
income
expenses
amounted
million
compared
million
first
half
first
half
took
account
recording
provision
million
relating
employment
safeguard
plan
first
half
takes
account
part
expenses
incurred
part
initial
public
offering
united
states
company
net
loss
stood
million
compared
million
first
half
inventiva
net
cash
flow
amounted
million
six
months
ended
june
compared
million
first
half
net
cash
used
operating
activities
million
million
first
half
respectively
addition
decrease
r
expenses
mentioned
first
half
cash
flow
operating
activities
positively
impacted
receipt
january
million
respect
research
tax
credit
cir
receipt
april
june
million
total
respect
cir
net
cash
financing
activities
amounted
million
first
half
driven
issuance
million
gross
proceeds
ordinary
shares
february
certain
existing
investors
company
entry
million
credit
agreement
guaranteed
french
state
syndicate
french
banks
consequently
inventiva
cash
cash
equivalents
stood
million
june
compared
million
december
financial
statements
first
half
approved
board
directors
september
statutory
auditors
issued
limited
review
report
details
inventiva
financial
report
available
company
website
financial
information
closing
accounts
july
inventiva
successfully
closed
initial
public
offering
nasdaq
global
market
aggregate
new
ordinary
shares
form
american
depositary
shares
adss
representing
one
ordinary
share
offering
price
per
ads
aggregate
gross
proceeds
initial
public
offering
deducting
underwriting
commissions
estimated
expenses
payable
company
approximately
million
securities
part
initial
public
offering
offered
inventiva
company
adss
listed
symbol
iva
began
trading
nasdaq
global
market
july
company
believes
cash
cash
equivalents
investments
financial
assets
together
net
proceeds
successful
initial
public
offering
nasdaq
global
market
cash
flow
operations
sufficient
fund
operations
fourth
quarter
main
areas
progress
r
portfolio
lanifibranor
steatohepatitis
nash
following
publication
positive
results
native
phase
iib
clinical
trial
evaluating
lanifibranor
nash
june
inventiva
progressed
analysis
circulating
biomarkers
first
results
analysis
shown
positive
statistically
significant
decrease
biomarkers
lanifibranor
treatment
importance
line
mechanism
action
lanifibranor
patients
treated
drug
candidate
showed
improvements
biomarkers
fibrosis
marker
fibrogenesis
ratio
ratio
depicting
inhibition
matrix
remodeling
process
apoptosis
marker
apoptosis
inflammation
ferritin
markers
inflammation
findings
including
table
appendix
press
release
presented
detail
tomorrow
webcast
conference
call
see
logistical
details
september
following
higher
expected
observed
effects
lanifibranor
reducing
steatosis
phase
iib
native
clinical
trial
nash
professor
kenneth
cusi
investigator
trial
decided
reduce
number
patients
ongoing
phase
ii
clinical
trial
evaluating
lanifibranor
type
diabetes
patients
fatty
liver
disease
nafld
results
expected
july
publication
positive
topline
results
phase
iib
native
nash
trial
validate
efficacy
clinical
trial
decision
continue
clinical
development
lanifibranor
nash
enter
pivotal
phase
iii
development
june
inventiva
announced
positive
topline
results
phase
iib
native
clinical
trial
evaluating
lanifibranor
treatment
nash
june
clinical
trial
lanifibranor
met
primary
endpoint
statistically
significant
reduction
steatosis
activity
fibrosis
score
saf
combines
assessments
hepatocellular
inflammation
ballooning
worsening
fibrosis
intention
treat
per
protocol
populations
drug
candidate
also
met
key
secondary
endpoints
including
nash
resolution
worsening
improvement
liver
fibrosis
worsening
itt
pp
populations
results
lanifibranor
first
drug
candidate
achieve
statistically
significant
results
nash
resolution
worsening
fibrosis
improvement
fibrosis
worsening
nash
two
food
drug
administration
fda
european
medicine
agency
ema
primary
endpoints
relevant
seeking
accelerated
approval
phase
iii
clinical
development
based
positive
topline
results
inventiva
decided
continue
clinical
development
lanifibranor
nash
enter
pivotal
phase
iii
development
approval
new
patent
directed
use
lanifibranor
treatment
several
fibrotic
diseases
including
nash
china
june
china
national
intellectual
property
administration
cnipa
may
odiparcil
mucopolysaccharidosis
type
vi
mps
vi
acceptance
investigational
new
drug
ind
application
odiparcil
mps
vi
food
drug
administration
fda
august
august
fda
accepted
inventiva
ind
application
odiparcil
treatment
mps
vi
allowing
company
initiate
clinical
trials
drug
candidate
decision
inventiva
extend
duration
phase
ii
safety
pharmacokinetics
pharmacodynamics
dose
escalating
study
clinical
trial
evaluating
odiparcil
mps
vi
children
months
following
scientific
advice
meeting
ema
july
launch
trial
expected
first
half
july
publication
inventiva
latest
research
odiparcil
mechanism
action
leading
scientific
journal
plos
one
showing
drug
candidate
associated
decreased
glycosaminoglycan
gag
accumulation
increased
gag
excretion
highlighting
distribution
mps
vi
tissues
organs
may
significant
milestones
appointment
dr
arun
sanyal
inventiva
scientific
advisory
board
sab
strengthening
board
expertise
field
nash
july
inventiva
reinforced
sab
field
nash
appointment
dr
arun
sanyal
july
professor
medicine
physiology
molecular
pathology
division
gastroenterology
virginia
commonwealth
university
vcu
medical
center
richmond
virginia
dr
sanyal
research
focuses
aspects
nafld
nash
well
complications
cirrhosis
liver
disease
also
serves
chairman
national
institutes
health
nih
nash
clinical
research
network
biomarkers
metabolic
liver
disease
nimble
consortium
liver
forum
nash
fibrosis
addition
participation
sab
dr
sanyal
involved
preparing
protocol
phase
iii
clinical
trial
development
lanifibranor
nash
entry
million
loan
facility
guaranteed
french
state
prêt
garanti
par
l
etat
support
bpifrance
crédit
agricole
société
générale
contributing
strengthening
company
cash
position
context
pandemic
may
capital
increase
million
subscribed
bvf
partners
new
enterprise
associates
nea
novo
holdings
sofinnova
partners
february
update
following
updated
recommendations
domestic
public
health
authorities
continuous
risk
assessment
pandemic
situation
inventiva
pursuing
implementation
measures
minimize
risks
employees
support
health
safety
unprecedented
time
today
r
internal
support
activities
expected
significantly
impacted
future
global
pandemic
continues
evolve
ultimate
impact
remains
uncertain
company
predict
full
extent
potential
delays
impacts
clinical
trials
potential
impact
business
inventiva
committed
continuing
implement
measures
aimed
minimizing
potential
business
impact
pandemic
continue
comply
updated
guidance
documents
regulatory
authorities
company
continues
closely
monitor
assess
respond
situation
evolves
overtime
continues
work
closely
authorities
contract
research
organizations
trial
sites
investigators
critically
reassess
existing
programs
communicates
appropriate
next
expected
key
milestones
end
native
phase
iib
clinical
trial
meeting
fda
scientific
advice
meeting
ema
planned
fourth
quarter
abbvie
completion
ongoing
phase
clinical
trial
psoriasis
patients
expected
fourth
quarter
preparation
commencement
phase
iii
clinical
trial
evaluating
lanifibranor
nash
planned
first
half
initiation
phase
ii
safety
pharmacokinetics
pharmacodynamics
dose
escalating
study
clinical
trial
evaluating
odiparcil
mps
vi
children
planned
first
half
initiation
phase
iia
extension
clinical
trial
odiparcil
mps
vi
patients
completed
prior
phase
iia
clinical
trial
improves
planned
first
half
upcoming
investor
conference
participation
wainwright
nd
annual
global
investment
virtual
conference
september
annual
global
investment
virtual
conference
september
roth
analyst
management
talk
series
september
annual
biotech
europe
forum
september
kbc
securities
virtual
life
sciences
conference
september
lyon
pôle
bourse
investment
forum
lyon
september
portzamparc
health
biotech
virtual
seminar
october
healthtech
innovation
days
paris
october
european
midcap
hybrid
event
paris
october
stifel
healthcare
conference
new
york
november
jefferies
th
global
healthcare
conference
london
november
global
healthcare
conference
london
november
piper
sandler
annual
healthcare
conference
new
york
december
upcoming
scientific
conference
presentations
presentation
phase
iib
native
clinical
trial
results
liver
aasld
american
association
study
liver
diseases
november
conference
call
conference
call
english
held
thursday
september
pm
paris
time
join
conference
call
please
use
code
dialing
one
following
numbers
france
belgium
germany
netherlands
switzerland
united
kingdom
united
states
presentation
accompanying
conference
call
available
inventiva
website
investors
results
presentations
section
time
followed
live
https
mmc
p
replay
conference
call
presentation
available
pm
paris
time
onwards
https
investors
next
financial
results
publication
revenues
cash
position
thursday
november
market
close
appendix
measure
circulating
biomarkers
native
phase
iib
trial
significant
decrease
lanifibranor
treatment
compared
placebo
median
relative
change
baseline
week
lanifibranor
placebo
fibrosis
µg
ml
baseline
ratio
p
apoptosis
p
inflammation
ferritin
p
p
level
estimated
fibrogenisis
active
corresponding
patients
fas
full
analysis
set
population
available
data
baseline
week
median
change
lanifibranor
statistically
significantly
different
compared
placebo
using
common
threshold
exploratory
wilcoxon
test
inventiva
inventiva
biopharmaceutical
company
focused
development
oral
small
molecule
therapies
treatment
nash
mps
diseases
significant
unmet
medical
need
leveraging
expertise
experience
domain
compounds
targeting
nuclear
receptors
transcription
factors
epigenetic
modulation
inventiva
currently
advancing
two
clinical
candidates
well
deep
pipeline
earlier
stage
programs
lanifibranor
lead
product
candidate
developed
treatment
patients
nash
common
progressive
chronic
liver
disease
currently
approved
therapies
inventiva
recently
announced
positive
topline
data
phase
iib
clinical
trial
evaluating
lanifibranor
treatment
patients
nash
inventiva
also
developing
odiparcil
second
clinical
stage
asset
treatment
patients
subtypes
mps
group
rare
genetic
disorders
phase
ii
clinical
trial
children
mps
vi
currently
preparation
following
release
positive
results
phase
iia
clinical
trial
adult
mps
vi
patients
end
parallel
inventiva
process
selecting
oncology
development
candidate
hippo
signalling
pathway
program
furthermore
company
established
strategic
collaboration
abbvie
area
autoimmune
diseases
abbvie
started
clinical
development
drug
candidate
treatment
moderate
severe
psoriasis
resulting
collaboration
inventiva
collaboration
enables
inventiva
receive
milestone
payments
upon
achievement
clinical
regulatory
commercial
milestones
addition
royalties
approved
products
resulting
collaboration
company
scientific
team
approximately
people
deep
expertise
fields
biology
medicinal
computational
chemistry
pharmacokinetics
pharmacology
well
clinical
development
also
owns
extensive
library
approximately
pharmacologically
relevant
molecules
approximately
proprietary
well
research
development
facility
inventiva
public
company
listed
compartment
c
regulated
market
euronext
paris
euronext
iva
isin
nasdaq
global
market
united
states
ticker
iva
contacts
inventiva
frédéric
cren
chairman
ceo
info
brunswick
group
yannick
tetzlaff
tristan
roquet
montegon
aude
lepreux
media
relations
inventiva
westwicke
icr
patricia
bank
investor
relations
important
notice
press
release
contains
statements
forecasts
estimates
respect
inventiva
clinical
trials
clinical
trial
data
releases
clinical
development
plans
anticipated
future
activities
inventiva
certain
statements
forecasts
estimates
recognized
use
words
without
limitation
believes
anticipates
expects
intends
plans
seeks
estimates
may
continue
similar
expressions
statements
historical
facts
rather
statements
future
expectations
statements
based
management
beliefs
statements
reflect
views
assumptions
prevailing
date
statements
involve
known
unknown
risks
uncertainties
could
cause
future
results
performance
future
events
differ
materially
expressed
implied
statements
actual
events
difficult
predict
may
depend
upon
factors
beyond
inventiva
control
guarantees
respect
pipeline
product
candidates
clinical
trial
results
available
anticipated
timeline
future
clinical
trials
initiated
anticipated
candidates
receive
necessary
regulatory
approvals
actual
results
may
turn
materially
different
anticipated
future
results
performance
achievements
expressed
implied
statements
forecasts
estimates
due
number
factors
including
inventiva
incurred
significant
losses
since
inception
inventiva
limited
operating
history
never
generated
revenue
product
sales
inventiva
require
additional
capital
finance
operations
inventiva
future
success
dependent
successful
clinical
development
regulatory
approval
subsequent
commercialization
current
future
product
candidates
preclinical
studies
earlier
clinical
trials
necessarily
predictive
future
results
results
inventiva
clinical
trials
may
support
inventiva
product
candidate
claims
inventiva
may
encounter
substantial
delays
clinical
trials
inventiva
may
fail
demonstrate
safety
efficacy
satisfaction
applicable
regulatory
authorities
enrollment
retention
patients
clinical
trials
expensive
process
could
made
difficult
rendered
impossible
multiple
factors
outside
inventiva
control
inventiva
product
candidates
may
cause
undesirable
side
effects
properties
could
delay
prevent
regulatory
approval
limit
commercial
potential
inventiva
faces
substantial
competition
inventiva
business
preclinical
studies
clinical
development
programs
timelines
financial
condition
results
operations
could
materially
adversely
affected
current
pandemic
given
risks
uncertainties
representations
made
accuracy
fairness
statements
forecasts
estimates
furthermore
statements
forecasts
estimates
speak
date
press
release
readers
cautioned
place
undue
reliance
statements
please
refer
universal
registration
document
filed
autorité
des
marchés
financiers
june
amendment
filed
july
well
financial
report
june
additional
information
relation
factors
risks
uncertainties
except
required
law
inventiva
intention
obligation
update
review
statements
referred
consequently
inventiva
accepts
liability
consequences
arising
use
statements
based
exchange
rate
per
euro
exchange
rate
published
european
central
bank
july
based
exchange
rate
per
euro
exchange
rate
published
european
central
bank
july
itt
includes
patients
randomized
trial
pp
includes
patients
paired
biopsies
without
deviation
impacting
efficacy
assessment
nash
resolution
worsening
fibrosis
defined
crn
lobular
inflammation
score
equal
crn
hepatocyte
ballooning
score
equal
worsening
score
improvement
liver
fibrosis
worsening
nash
defined
improvement
score
stage
increase
score
increase
score
increase
score
attachment
